GlassScriptPhysician profile
Soledad Triana
NPI 1306320858
$5,432.82
in general payments reported to CMS, 2019-2025
26 companies · $1,838 in 2025
The $1,838 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,631 · 2023: $423 · 2024: $1,541 · 2025: $1,838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,602 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,602.34 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $979.26 | 2022-2025 | |
| Janssen Biotech, INC. | $635.76 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $454.47 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $435.73 | 2024-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $383.70 | 2022-2025 | Dupixent |
| Galderma Laboratories, L.P. | $379.97 | 2022-2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $333.07 | 2022-2025 | Blu-U, Ilumya |
| Pfizer INC. | $282.08 | 2022-2025 | |
| Incyte Corporation | $216.87 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $177.62 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $173.67 | 2023-2024 | Sotyktu |
| Leo Pharma INC. | $160.53 | 2022-2025 | Anzupgo, Adbry |
| Lilly USA, LLC | $156.71 | 2022-2025 | Taltz, Ebglyss |
| Allergan, INC. | $117.62 | 2022 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $71.70 | 2025 | Vtama |
| Verrica Pharmaceuticals INC. | $62.70 | 2024-2025 | Ycanth |
| Dermavant Sciences, INC. | $61.42 | 2024 | Vtama |
| Biofrontera INC. | $54.06 | 2022-2025 | Bf-Rhodoled, Ameluz, Xepi |
| Almirall LLC | $41.43 | 2022-2025 | Seysara |
| Ucb, INC. | $39.73 | 2025 | Bimzelx |
| Amgen INC. | $31.97 | 2024 | Otezla |
| Mayne Pharma Commercial LLC | $29.45 | 2024 | |
| Kyowa Kirin, INC. | $27.01 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.51 | 2024 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Soledad Triana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.